Houlihan Lokey, Inc. Class A (HLI)
Live price chart, market sentiment, and community perspectives for Houlihan Lokey, Inc. Class A (NYSE: HLI).
Live price chart, market sentiment, and community perspectives for Houlihan Lokey, Inc. Class A (NYSE: HLI).
As a hedge fund portfolio manager reviewing HLI's latest reports, I am noting the recent drop in Q1 fiscal 2027 revenue to $511 million compared to $605 million a year prior. While management continues to frame these Corporate Finance headwinds as temporary, the introduction of a new shelf registration in August 2026 adds uncertainty regarding future capital allocation and potential dilution pressures.
When evaluating HLI's fundamental moat during analyst briefings, one must weigh their structural market dominance—retaining the crown as the No. 1 global restructuring advisor for 11 consecutive years—against immediate revenue compression. Net income attributable to the firm dropped to $78 million this past quarter, proving that even top-tier advisory franchises are vulnerable to cyclical advisory dry spells.
From a quantitative risk perspective, HLI is currently trading near a neutral sentiment zone with mid-channel oscillation patterns. Our models indicate a short setup targeting a 10.1% downside relative to a minimal 0.3% risk parameter. Given the recent institutional churn showing 287 fewer tracked 13F holders quarter-over-quarter, caution is warranted before establishing aggressive long positions.
Looking at the options and derivatives desk, the recent announcement of a $0.70 per share dividend for the second quarter of fiscal 2027 provides a modest income floor for HLI shareholders. However, insider net activity over the past 180 days showing a negative $513K net balance suggests that insiders are not aggressively buying the recent dips following the 15.6% year-on-year revenue drop.
From a boutique investment banking research standpoint, HLI's brand equity remains virtually peerless in fairness opinions and restructuring. Yet, the wider market is currently punishing capital markets firms that miss consensus expectations by double-digit percentages. The 16.3% revenue miss reported in their challenging second quarter requires us to closely monitor deal flow recovery in the Americas and Europe before upgrading our targets.
Explore plasma cleansing, somatic organ swaps, and BCI.